Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | NK CAR-based therapies & future perspectives

Tobias Bexte • 31 Aug 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T NK-Cell Therapy

Tobias Bexte, cand.med., University Hospital Frankfurt, Goethe University, Frankfurt, Germany, gives an outlook on natural killer (NK) chimeric antigen receptor (CAR)-based therapies and what the future may look like. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tobias Bexte

Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells
3:33
Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells
Tobias Bexte • 25 Apr 2023
Gene editing of NKG2A to enhance NK cell cytotoxicity against multiple myeloma cells
1:19
Gene editing of NKG2A to enhance NK cell cytotoxicity against multiple myeloma cells
Tobias Bexte • 16 Mar 2022
Advantages of primary NK cells for the treatment of patients with hematological malignancies
0:48
Advantages of primary NK cells for the treatment of patients with hematological malignancies
Tobias Bexte • 16 Mar 2022
Next steps for gene-edited NK cells in the treatment of hematological malignancies
0:59
Next steps for gene-edited NK cells in the treatment of hematological malignancies
Tobias Bexte • 16 Mar 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals